GBIM Stock Overview
A biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
GlobeImmune, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -99.99% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| GBIM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 4.3% | 1.6% |
| 1Y | n/a | 18.8% | 32.3% |
Return vs Industry: Insufficient data to determine how GBIM performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how GBIM performed against the US Market.
Price Volatility
| GBIM volatility | |
|---|---|
| GBIM Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GBIM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine GBIM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | n/a | n/a | www.globeimmune.com |
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer.
GlobeImmune, Inc. Fundamentals Summary
| GBIM fundamental statistics | |
|---|---|
| Market cap | US$5.00 |
| Earnings (TTM) | -US$2.07m |
| Revenue (TTM) | US$6.21m |
0.0x
P/S Ratio0.0x
P/E RatioIs GBIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GBIM income statement (TTM) | |
|---|---|
| Revenue | US$6.21m |
| Cost of Revenue | US$2.08m |
| Gross Profit | US$4.13m |
| Other Expenses | US$6.20m |
| Earnings | -US$2.07m |
Last Reported Earnings
Mar 31, 2016
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did GBIM perform over the long term?
See historical performance and comparison